Insider Trading Alert - WPX, ANDE And ABMD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 28, 2014, 121 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $341.00 to $1,468,820,910.70.

Highlighted Stocks Traded by Insiders:

WPX Energy (WPX) - FREE Research Report

Kindick Kelt, who is Director at WPX Energy, bought 5,000 shares at $20.80 on May 28, 2014. Following this transaction, the Director owned 26,276 shares meaning that the stake was boosted by 23.5% with the 5,000-share transaction.

The shares most recently traded at $21.26, up $0.46, or 2.16% since the insider transaction. Historical insider transactions for WPX Energy go as follows:

  • 4-Week # shares bought: 8,000
  • 4-Week # shares sold: 167,253
  • 12-Week # shares bought: 8,000
  • 12-Week # shares sold: 167,253
  • 24-Week # shares bought: 8,000
  • 24-Week # shares sold: 202,907

The average volume for WPX Energy has been 4.0 million shares per day over the past 30 days. WPX Energy has a market cap of $4.3 billion and is part of the basic materials sector and energy industry. Shares are up 5.1% year-to-date as of the close of trading on Wednesday.

WPX Energy, Inc., an independent natural gas and oil exploration and production company, is engaged in the exploitation and development of unconventional properties in the United States. Currently, there are 2 analysts who rate WPX Energy a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WPX - FREE

TheStreet Quant Ratings rates WPX Energy as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full WPX Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Andersons (ANDE) - FREE Research Report

Reed Harold M, who is Chief Operating Officer at Andersons, bought 2,000 shares at $45.16 on May 28, 2014. Following this transaction, the Chief Operating Officer owned 43,830 shares meaning that the stake was boosted by 4.78% with the 2,000-share transaction.

The shares most recently traded at $50.50, up $5.34, or 10.57% since the insider transaction. Historical insider transactions for Andersons go as follows:

  • 4-Week # shares bought: 965
  • 4-Week # shares sold: 4,098
  • 12-Week # shares bought: 965
  • 12-Week # shares sold: 7,629
  • 24-Week # shares bought: 965
  • 24-Week # shares sold: 23,027

The average volume for Andersons has been 302,900 shares per day over the past 30 days. Andersons has a market cap of $1.3 billion and is part of the consumer goods sector and food & beverage industry. Shares are down 14.31% year-to-date as of the close of trading on Wednesday.

The Andersons, Inc. is engaged in the grain, ethanol, plant nutrient, railcar leasing, turf and cob products, and consumer retailing businesses. It operates in six segments: Grain, Ethanol, Rail, Plant Nutrient, Turf & Specialty, and Retail. The stock currently has a dividend yield of 0.95%. The company has a P/E ratio of 13.1. Currently, there are no analysts who rate Andersons a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANDE - FREE

TheStreet Quant Ratings rates Andersons as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Andersons Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Abiomed (ABMD) - FREE Research Report

Bolt William J, who is SVP, QA and Regulatory Affairs at Abiomed, sold 8,029 shares at $21.10 on May 28, 2014. Following this transaction, the SVP, QA and Regulatory Affairs owned 86,176 shares meaning that the stake was reduced by 8.52% with the 8,029-share transaction.

Minogue Michael R, who is President, CEO, Chairman at Abiomed, sold 90,001 shares at $21.19 on May 28, 2014. Following this transaction, the President, CEO, Chairman owned 170,911 shares meaning that the stake was reduced by 34.49% with the 90,001-share transaction.

Bowen Robert, who is Chief Financial Officer at Abiomed, sold 6,820 shares at $21.11 on May 28, 2014. Following this transaction, the Chief Financial Officer owned 59,119 shares meaning that the stake was reduced by 10.34% with the 6,820-share transaction.

Greenfield Andrew J, who is VP Healthcare Solutions at Abiomed, sold 7,026 shares at $21.10 on May 28, 2014. Following this transaction, the VP Healthcare Solutions owned 54,047 shares meaning that the stake was reduced by 11.5% with the 7,026-share transaction.

Weber David M, who is Chief Operating Officer at Abiomed, sold 10,172 shares at $21.11 on May 28, 2014. Following this transaction, the Chief Operating Officer owned 120,310 shares meaning that the stake was reduced by 7.8% with the 10,172-share transaction.

Howley Michael G, who is VP, Global Sales & Marketing at Abiomed, sold 9,223 shares at $21.11 on May 28, 2014. Following this transaction, the VP, Global Sales & Marketing owned 65,263 shares meaning that the stake was reduced by 12.38% with the 9,223-share transaction.

The shares most recently traded at $21.72, up $0.61, or 2.82% since the insider transaction. Historical insider transactions for Abiomed go as follows:

  • 4-Week # shares sold: 990
  • 12-Week # shares sold: 990
  • 24-Week # shares sold: 990

The average volume for Abiomed has been 467,200 shares per day over the past 30 days. Abiomed has a market cap of $857.3 million and is part of the health care sector and health services industry. Shares are down 18.81% year-to-date as of the close of trading on Wednesday.

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The company has a P/E ratio of 119.6. Currently, there are 4 analysts who rate Abiomed a buy, 2 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABMD - FREE

TheStreet Quant Ratings rates Abiomed as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and premium valuation. Get the full Abiomed Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Online Retailers Hit by Supreme Court Ruling Requiring Sales Tax Collection

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech